<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230228057570N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-12</date_registration>
      <primary_sponsor>Ilam University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of ketamine and pethidine on pain control</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effects of ketamine and pethidine on pain control after surgery in upper and lower limbs orthopedic surgery candidates</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68914</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Balance block randomization method will be used for random allocation of participants. for that, 6 blocks with 4 permutations will be created in the following order
1=KKPP
2=KPKP
3=KPPK
4=PKPK
5=PPKK
6=PKKP
where P represents pethidine group and K represents ketamine group. Then, based on the numbers in the random table, a number will be chosen randomly, and based on the last digit on the right, one of the groups will be used to determine the sequence of randomization. It should be noted that if the number on the right side is zero or 7 to 9 when choosing a random number, that number will not be considered and a random number will be selected again. This process, will continue until all 80 participants are assigned to two groups. It should be noted that this method will prevent the unbalance of the two groups as well as the identification of the randomization sequence, Blinding description: For blinding, each drug will be assigned a code that can only be identified by the principal investigator and neither the patient nor the person who is collecting data will unknow what drug the patient has taken. For this purpose, the same cover and appearance of the medicine vials will be prepared.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Fracture of upper limb. Condition 2: Fracture of lower limb.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The patients in the ketamine group will receive ketamine at a dose of 0.3mg/kg 30 minutes after the induction of anesthesia. For this purpose, the patients will undergo standard monitoring (pulse oximetry, heart rate, blood pressure, and echocardiography) before surgery, and the vital signs of the patients will be evaluated and recorded every 5 minutes in the first 15 minutes. Then this process repeated every 15 minutes. Induction of anesthesia in all patients is as follows: they will be anesthetized with 2mg/kg propofol, 2ug/kg fentanyl, and 0.5mg/kg atracurium, and then the patients will undergo tracheal intubation. Anesthesia will be continued with a mixture of oxygen and nitrous oxide in equal proportions and isoflurane equivalent to MAC and continuous injection of atracurium at a dose of 0.2mg/kg. Intervention 2: Control group: for patients in the pethidine group, the extubation will be done after surgery and in a suitable situation. When patients get consciousness, pethidine will be injected with the dose of 1mg/kg slowly and intravenously, then the patients will be transferred to recovery and under standard monitoring again.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamed Azadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Haidari street, Ilam</address>
        <city>Ilam</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6931975397</zip>
        <telephone>+98 84 3333 4500</telephone>
        <email>azadi_eyvan_2012@yahoo.com</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reza Pakzad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ilam University of Medical Sciences campus, Banganjab, Research Blvd</address>
        <city>Ilam</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6939177143</zip>
        <telephone>+98 84 3222 7134</telephone>
        <email>rezapakzad2010@yahoo.com</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>candidate for elective orthopedic surgery with general anesthesia and class l and ll in the ASA classification
Age range from 18 to 60 years
No history of opioid addiction
Absence of underlying diseases such as: liver and kidney failure, history of seizures, pregnancy and breastfeeding, high ICP (intracranial pressure) and glaucoma, thyrotoxicosis, high blood pressure, diabetes, heart disease and history of disease respiratory
No history of disorders such as mental retardation or psychological illness
No history of drug sensitivity to pethidine or ketamine
No history of chronic use of painkillers</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>opioid addiction
underlying diseases such as: liver and kidney failure, history of seizures, pregnancy and breastfeeding, high ICP (intracranial pressure) and glaucoma, thyrotoxicosis, high blood pressure, diabetes, heart disease and history of disease respiratory
mental retardation or psychological illness
drug sensitivity to pethidine or ketamine
chronic use of painkillers</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T10</hc_code>
      <hc_code>S82</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of upper limb, level unspecified</hc_keyword>
      <hc_keyword>Fracture of lower leg, including ankle</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The patients in the ketamine group will receive ketamine at a dose of 0.3mg/kg 30 minutes after the induction of anesthesia. For this purpose, the patients will undergo standard monitoring (pulse oximetry, heart rate, blood pressure, and echocardiography) before surgery, and the vital signs of the patients will be evaluated and recorded every 5 minutes in the first 15 minutes. Then this process repeated every 15 minutes. Induction of anesthesia in all patients is as follows: they will be anesthetized with 2mg/kg propofol, 2ug/kg fentanyl, and 0.5mg/kg atracurium, and then the patients will undergo tracheal intubation. Anesthesia will be continued with a mixture of oxygen and nitrous oxide in equal proportions and isoflurane equivalent to MAC and continuous injection of atracurium at a dose of 0.2mg/kg.</i_keyword>
      <i_keyword>Control group: for patients in the pethidine group, the extubation will be done after surgery and in a suitable situation. When patients get consciousness, pethidine will be injected with the dose of 1mg/kg slowly and intravenously, then the patients will be transferred to recovery and under standard monitoring again.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score based on Visual Analogue Scale tool. Timepoint: at recovery room, 6 and 12 hours after surgery. Method of measurement: Visual Analogue Scale tools.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ilam University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-18</approval_date>
        <contact_name>Ethics committee of Ilam University of Medical Sciences</contact_name>
        <contact_address>Ilam University of Medical Sciences campus, Banganjab, Pazhohesh Blvd Ilam Ilam Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
